In postmenopausal women at high risk for fracture, romosozumab for 3 mo was noninferior to 12 mo for increasing total hip BMD at 1 y.
Where this comes from
- Record sourced from PubMed, PMID 42081814.
- Also identified by DOI 10.7326/ANNALS-26-01143-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Geriatrics:[Formula: see text] Rheumatology:[Formula: see text].
Medical subject headings
- Bone Density
- Osteoporosis, Postmenopausal
- Antibodies, Monoclonal
- Bone Density Conservation Agents
- Osteoporotic Fractures